TIDE (Tumor Immune Dysfunction and Exclusion) is a computational framework that is used to predict response to immune checkpoint inhibitors (ICIs) in cancer patients. It uses gene expression data from tumor samples to estimate the degree of immune dysfunction and exclusion within the tumor microenvironment, which can help predict whether a patient is likely to respond to ICIs or not. TIDE has been shown to have high predictive accuracy for response to ICIs across multiple cancer types.